A new study has found a promising new treatment for patients with behavioral variant fronto-temporal dementia, the second most common form of dementia in the under 60s -- resulting in a stabilizing of what would normally be escalating behavioral issues, and a slowing of brain shrinkage due to the disease. It is the second clinical trial to show that the drug, sodium selenate, may slow cognitive decline and neuro-degenerative damage that is the hallmark of many dementias including Alzheimer's Disease.